Cell Line License for Protein Production

This is a Pre-solicitation Notice of a proposed contract action, not a request for quotations (RFQ). The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with DNA TwoPointO Inc. (doing business as ATUM Biosciences) to procure a license for ATUM proprietary technology to produce cell lines for the production of a protein (engineered antibody) to be tested in clinical trials. Period of Performance for this license shall be a base of one (1) year and two (2) option years.

The Vaccine Translational Research Branch of the Division of AIDS (DAIDS) funds and manages the manufacturing of candidate HIV vaccines and treatments. The purpose of this acquisition is to acquire a non-exclusive, non-transferable, fee-bearing license to produce engineered antibodies by using the ATUM Protein Expressing Cell Lines technology. This will allow VTRB to produce biological products for production of monoclonal antibody therapeutics from mammalian cells, excluding any uses in cell therapy or gene therapy. The technology involved with this license is the Leap In transposon technology, which is proprietary to ATUM Biosciences (formerly DNA2.0). This specific cell line is required as it is related to the manufacture of an engineered bnAB through the NIAID preclinical master contract to ABL, Inc. (Contract No. HHSN272201700010I, Task Order HHSN27200009 cGMP Manufacturing of Monoclonal Antibodies).

The statutory authority for this sole source requirement is 41 U.S.C. 253(c)(1) as implemented by FAR 6. 302-1 only one responsible source and no other supply or service will satisfy agency requirements. THIS IS NOT A REQUEST FOR QUOTATIONS (RFQ). All responsible sources that could provide this supply/service may submit a capability statement that will be considered by email (subject line to reference NIAID-NOI20-2000387) to Julie Yun at julie.yun@nih.gov by January 3, 2020 8:00AM Eastern. All responses that meet the agency requirement and are received by the closing date of this Notice will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government

SPECIAL NOTICE

Offerors are advised that the Government may share your information with non-government personnel who are assisting with the evaluation of responses. The exclusive responsibility for source selection will reside with the Government. By submitting your response, you consent to disclosure of your offer to non-government personnel for purposes of evaluation.